Evogene reports Q1 EPS (38c) vs. (76c) last year

Reports Q1 revenue 2.4M vs. $4.2M last year. Q1 of FY24 revenue included license fee payments totaling $3.5M-$2.5M from Lavie Bio’s license fee under its collaboration with Corteva, and $1.0M from AgPlenus’ license fee under its collaboration with Bayer. The primary driver of revenue in the Q1 of 2025 was an increase in seed sales by Casterra. As of March 31, Evogene (EVGN) held consolidated cash, cash equivalents, and short-term bank deposits of approximately $9.8M, compared to approximately $15.3M as of December 31, 2024.Ofer Haviv, Evogene’s President and CEO, stated: “As part of our ongoing strategy to build a more capital-efficient and value-driven business model, Evogene is focusing on two key priorities: unlocking the full potential of our ChemPass-AI tech-engine in the pharmaceutical sector, and generating cash flow and strategic value from our subsidiaries. These efforts are designed to accelerate near-term monetization opportunities while reinforcing our long-term growth trajectory. We’ve made significant progress in advancing ChemPass-AI tech-engine, our proprietary AI platform for small molecule drug discovery. Over the past quarter, we sharpened its value proposition for the pharma and biotech industries, with a clear focus on addressing a core challenge-designing highly potent, novel compounds that meet complex multi-parameter requirements. An example of our unique ChemPass-AI offering is the foundation model developed in collaboration with Google Cloud, at the core of our lead-optimization activity.”